ストックスクリーナーアプリを入手
1.305
1.14%
-0.015
前日終値:
$1.32
開ける：
$1.31
24時間の取引高:
253.36K
Relative Volume:
0.29
時価総額：
$84.92M
収益：
-
当期純損益:
$-37.34M
株価収益率:
-0.8419
EPS:
-1.55
ネットキャッシュフロー:
$-36.91M
1週間 パフォーマンス:
+7.85%
1か月 パフォーマンス:
-1.14%
6か月 パフォーマンス:
+18.64%
1年 パフォーマンス:
-18.94%
1日の値動き範囲:
$1.26
$1.32
1週間の範囲:
$1.19
$1.35
52週間の値動き範囲:
$0.4986
$1.90
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
名前
Sellas Life Sciences Group Inc
セクター
電話
(646) 200-5278
住所
7 TIMES SQUARE, NEW YORK, NY
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-07-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 開始されました | Oppenheimer | Outperform |
| 2018-04-02 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-19 | アップグレード | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc (SLS) 最新ニュース
How to interpret SELLAS Life Sciences Group Inc (SLS)’s stock chart patterns - US Post News
SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 3.3% - MarketBeat
SELLAS Life Sciences Group Inc (SLS)’s stock performance: a year in review - US Post News
SELLAS Life Sciences Group Inc (SLS) can make a big difference with a little luck - SETE News
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Drop in Short Interest - MarketBeat
Market Highlights: SELLAS Life Sciences Group Inc (SLS) Ends on a High Note at 1.32 - The Dwinnex
Healthy Upside Potential: SELLAS Life Sciences Group Inc (SLS) - SETE News
Ratios Uncovered: Breaking Down SELLAS Life Sciences Group Inc (SLS)’s Trailing Twelve Months Metrics - The Dwinnex
A closer look at SELLAS Life Sciences Group Inc (SLS)’s stock price trends - US Post News
It makes sense and dollars to buy SELLAS Life Sciences Group Inc (SLS) stock - SETE News
SELLAS Life Sciences Group (NASDAQ:SLS) Issues Quarterly Earnings Results - Defense World
SELLAS Life Sciences Group (NASDAQ:SLS) Posts Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
SLSSELLAS Life Sciences Group, Inc. Latest Stock News & Market Updates - StockTitan
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update - The Bakersfield Californian
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update - StockTitan
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
SELLAS Life Sciences Group (NASDAQ:SLS) Trading 0.9% Higher - MarketBeat
SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 0.9% - Defense World
SELLAS gains orphan drug status in EU for PTCL treatment - Investing.com
SELLAS gains orphan drug status in EU for PTCL treatment By Investing.com - Investing.com Canada
Market Recap Check: SELLAS Life Sciences Group Inc (SLS)’s Negative Finish at 1.16, Up/Down -3.33 - The Dwinnex
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas - GlobeNewswire
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas - StockTitan
Here’s Why SELLAS Life Sciences Group Inc (NASDAQ: SLS) Is A Good Stock To Buy Right Now - Stocks Register
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas - Yahoo Finance
This trade activity should not be overlooked: SELLAS Life Sciences Group Inc (SLS) - SETE News
SEC Form 424B5 filed by SELLAS Life Sciences Group Inc. - Quantisnow
SELLAS Life Sciences to raise fresh capital via direct offering - Investing.com India
SELLAS Life Sciences to raise fresh capital via direct offering By Investing.com - Investing.com Canada
SELLAS Life Sciences to raise fresh capital via direct offering - Investing.com
SELLAS Life Sciences to raise fresh capital via direct offering By Investing.com - Investing.com Australia
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market - GlobeNewswire
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market - StockTitan
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to ... - WDRB
SLS’s Stock Market Adventure: 36.55% YTD Growth Amidst Volatility - The InvestChronicle
Holdings of SELLAS Life Sciences Group Inc (SLS) are aligned with the stars - SETE News
Investing in SELLAS Life Sciences Group Inc (SLS) might be a great opportunity, but the stock is a bit overvalued - US Post News
Taking on analysts’ expectations and winning: SELLAS Life Sciences Group Inc (SLS) - SETE News
Investors Buy High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS) - Defense World
Metric Deep Dive: Understanding SELLAS Life Sciences Group Inc (SLS) Through its Ratios - The Dwinnex
SELLAS gains FDA nod for pediatric leukemia treatment - Investing.com India
SELLAS gains FDA nod for pediatric leukemia treatment - Investing.com
SELLAS Announces U.S. FDA Rare Pediatric Disease - GlobeNewswire
SELLAS Life Sciences Group Inc (SLS) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Financial Analysis: SELLAS Life Sciences Group Inc (SLS)’s Ratios Unveil Key Insights - The Dwinnex
What is the investor’s view on SELLAS Life Sciences Group Inc (SLS)? - US Post News
SELLAS Receives European Medicines Agency Orphan Drug - GlobeNewswire
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia - StockTitan
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia - Yahoo Finance
Upward Trajectory: SELLAS Life Sciences Group Inc (SLS) Posts a Gaine, Closing at 1.14 – DWinneX - The Dwinnex
Sellas Life Sciences Group Inc (SLS) 財務データ
収益
当期純利益
現金流量
EPS
1.26%
1.94%
大文字化:
|
ボリューム (24 時間):